Research Statement
My scientific focus is leukemia, specifically myeloproliferative neoplasms (MPN) including CML, chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF). As a clinician-scientist with a translational research focus I am heading an extramurally funded research laboratory that is dedicated to the study of signaling pathways, drug resistance and new molecular therapies in leukemia. My work describing the selective effects of imatinib on CML cells provided the rationale for clinical trials that led to the approval of Gleevec as the first molecularly-based therapy for leukemia. Current work in my lab is focused on understanding the role of the bone marrow microenvironment in leukemia drug resistance, discovering novel therapeutic targets and developing more specific signal transduction inhibitors. My work encompasses more than 200 articles in the peer-reviewed literature, including journals like Cancer Cell, Blood, Journal of Clinical Investigation and the New England Journal of Medicine. I have co-authored more than 10 book chapters, with contributions in leading textbooks such as deVita’s Principles of Oncology. I am a regular speaker at major international scientific meetings, such as the American Society of Hematology and the European Hematology Association and a peer reviewer for journals like Nature Genetics and Cancer Cell. Honors include the Alexandra Kefalides Prize for Leukemia Research, membership on the Editorial Board of Blood (the leading journal in Hematology) and Thompson Reuters Highly Cited Researcher award in 2014 and 2015. I serve as the vice-Chair for NCCN CML panel and am a member of the NCCN MPN panel. I am also a standing member of the Developmental Therapeutics Study Section, Center for Scientific Review.
Research Keywords
- Myeloproliferative Neoplasms
- Leukemia Drug Resistance
- Chronic myeloid leukemia
- Autologous Stem Cell Transplantation
Languages
- English, fluent.
- German, fluent.
- Russian, fluent.